X

Trial Profile

A Phase I/II Randomized, Double-blind, Placebo-controlled Study of Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha-2b (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use
Acronyms IN2COVID

Most Recent Events

26 Jan 2023 According to a BetterLife Pharma media release, data analysis of this study is ongoing.
03 Aug 2022 Status changed from active, no longer recruiting to completed.
28 Apr 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com